All News #Library
Others
Regen Bio Explores HemaXellerate`s Impact on Chemotherapy Market
15 Aug 2025 //
GLOBENEWSWIRE
Regen BioPharma Expands Vision For HemaXellerate™ Phase 1 Trial
19 Nov 2024 //
GLOBENEWSWIRE
Regen issues Message to the Shareholders from the Chairman And CEO
19 Dec 2022 //
PRNEWSWIRE
Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic
18 Nov 2022 //
PRNEWSWIRE
Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space
26 Oct 2022 //
PRNEWSWIRE
Regen Files Provisional Patent on CAR-T Cell Capable of Educating Naïve T Cells
05 Oct 2022 //
PRNEWSWIRE
Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy
25 Aug 2022 //
PRNEWSWIRE
Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach
11 Aug 2022 //
PRNEWSWIRE
Regen BioPharma Files Provisional Patent for Survivin mRNA Cancer Vaccine
26 Jul 2022 //
PRNEWSWIRE
Regen BioPharma. Responds to Numerous Requests for Updates on its IP Portfolio
16 Mar 2022 //
PRNEWSWIRE
Regen BioPharma Announces Program to Fast-Track its Checkpoint Inhibitor Program
10 Mar 2022 //
PRNEWSWIRE
Oncology Pharma, Regen Bio to Jointly Develop Modified mRNA anti-Cancer Vaccine
14 Feb 2022 //
ACCESSWIRE

Market Place
Sourcing Support